Renée Aguiar-Lucander Joins Inventiva's Board of Directors

Inventiva, a biopharmaceutical company, has announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The shareholders approved this addition during the company's recent Annual General Meeting. Mark Pruzanski, Chairman of Inventiva, emphasized Aguiar-Lucander's significant industry experience as the company moves into crucial stages of clinical development.

Renée Aguiar-Lucander, currently CEO of Hansa Biopharma, previously led Calliditas Therapeutics to a successful NASDAQ listing and acquisition by Asahi Kasei. Her leadership secured FDA approval for a unique IgA nephropathy treatment.

Inventiva focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its lead product, lanifibranor, in the Phase 3 trial stage.